A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction



Status:Recruiting
Conditions:Angina, Peripheral Vascular Disease, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 125
Updated:7/26/2018
Start Date:June 29, 2018
End Date:June 1, 2020
Contact:Dalisa Espinosa
Email:dalisa.espinosa@nyumc.org
Phone:212-263-5656

Use our guide to learn which trials are right for you!

Among patients with stable ischemic heart disease who are referred for coronary angiography,
a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based
on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40%
of these patients. However, the mechanisms and optimal treatment of coronary microvascular
dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized
as mechanisms of microvascular dysfunction. Investigators plan to evaluate association
between platelet activity, inflammation, and coronary microvascular dysfunction in stable
women referred for coronary angiography, and to identify non-invasive correlates of coronary
microvascular dysfunction in these patients.

The objectives of this study are to

1. Investigate platelet activity and inflammation in patients with and without coronary
microvascular disease who are referred for coronary angiography for the evaluation of
stable ischemic heart disease and are found to have non-obstructuve epicardial CAD

2. To identify correlates of coronary microvascular dysfunction in non coronary
microvascular beds that can be characterized in vivo.

Inclusion Criteria:

- Adult women age ≥18 years referred for coronary angiography

- Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia
by stress testing

- Administration of aspirin therapy prior to cardiac catheterization

Exclusion Criteria:

Pre-Cath Exclusion criteria:

- Active bleeding and/or bleeding diathesis

- Anemia (hemoglobin <9 mg/dl)

- Known thrombocytosis (platelet count >500,000)

- Know thrombocytopenia (platelet count <100,000)

- NSAIDs (e.g., ibuprofen, naproxen) within 3 days

- Platelet antagonists other than aspirin and thienopyridines, within 7 days

- Prior percutaneous coronary intervention or coronary artery bypass grafting

- Acute myocardial infarction within 3 months

- Severe valvular heart disease

- Cardiogenic shock or mechanical circulatory support

- New York Heart Association (NYHA) Functional Class III or IV heart failure

- Ejection Fraction <40%

- Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy

- Pregnancy

- Contraindication to intravenous infusion of adenosine during coronary angiography, due
to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or
bronchospastic lung disease (severe asthma), second- or third-degree AV block (except
in patients with a functioning artificial pacemaker), or sinus node disease, such as
sick sinus syndrome or symptomatic bradycardia,

Angiographic Exclusion criteria:

- Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by
invasive coronary angiography)

- Unfavorable coronary artery anatomy for guidewire positioning (as determined by the
angiographer or PI)
We found this trial at
1
site
550 1st Ave
New York, New York 10016
(212) 263-7300
Principal Investigator: Harmony Reynolds, MD
Phone: 212-263-5656
New York University School of Medicine NYU School of Medicine has a proud history that...
?
mi
from
New York, NY
Click here to add this to my saved trials